Eli Lilly 2013 Annual Report Download - page 41

27
The following table summarizes our revenue activity in 2012 compared with 2011:
Year Ended Year Ended
December 31, 2012 December 31,
2011
Percent
Change from
Product U.S.(1) Outside U.S. Total Total 2011
(Dollars in millions)
Cymbalta . . . . . . . . . . . . . . . . . . . . . . . $ 3,917.8 $ 1,076.3 $ 4,994.1 $ 4,161.8 20
Alimta . . . . . . . . . . . . . . . . . . . . . . . . . . 1,122.4 1,471.9 2,594.3 2,461.1 5
Humalog . . . . . . . . . . . . . . . . . . . . . . . 1,370.9 1,024.6 2,395.5 2,367.6 1
Cialis . . . . . . . . . . . . . . . . . . . . . . . . . . 782.2 1,144.6 1,926.8 1,875.6 3
Zyprexa . . . . . . . . . . . . . . . . . . . . . . . . 360.4 1,341.0 1,701.4 4,622.0 (63)
Humulin . . . . . . . . . . . . . . . . . . . . . . . . 592.1 647.0 1,239.1 1,248.8 (1)
Forteo . . . . . . . . . . . . . . . . . . . . . . . . . 488.2 662.8 1,151.0 949.8 21
Evista . . . . . . . . . . . . . . . . . . . . . . . . . . 699.5 310.6 1,010.1 1,066.9 (5)
Strattera . . . . . . . . . . . . . . . . . . . . . . . . 384.1 237.3 621.4 620.1 —
Effient. . . . . . . . . . . . . . . . . . . . . . . . . . 339.0 118.2 457.2 302.5 51
Other pharmaceutical products . . . . . . 593.4 1,249.6 1,843.0 2,250.0 (18)
Animal health products . . . . . . . . . . . . 1,161.8 874.7 2,036.5 1,678.6 21
Total net product sales. . . . . . . . . . . 11,811.8 10,158.6 21,970.4 23,604.8 (7)
Collaboration and other revenue(2). . . . 501.3 131.7 633.0 681.7 (7)
Total revenue. . . . . . . . . . . . . . . . . . $ 12,313.1 $ 10,290.3 $ 22,603.4 $ 24,286.5 (7)
1 U.S. revenue includes revenue in Puerto Rico.
2 Collaboration and other revenue consists primarily of royalties for Erbitux and revenue associated with exenatide in the United States.
Sales of Cymbalta increased 23 percent in the U.S., due to higher prices and, to a lesser extent, increased
demand. Sales outside the U.S. increased 9 percent, driven by increased demand, partially offset by the
unfavorable impact of foreign exchange rates.
Sales of Alimta increased 13 percent in the U.S., driven by increased demand and higher prices. Sales
outside the U.S. remained flat, as increased demand was offset by lower prices in Japan and the unfavorable
impact of foreign exchange rates.
Sales of Humalog decreased 2 percent in the U.S., due to increased government and commercial rebates as
well as the product's removal from a large formulary in 2012. Sales outside the U.S. increased 6 percent, due
to increased demand, partially offset by the unfavorable impact of foreign exchange rates.
Sales of Cialis increased 11 percent in the U.S., driven by increased demand and higher prices. Sales outside
the U.S. decreased 2 percent, driven by the unfavorable impact of foreign exchange rates, partially offset by
increased demand and higher prices.
Sales of Zyprexa decreased 83 percent in the United States. Sales outside the U.S. decreased 45 percent.
The decreases were due to the loss of patent exclusivity in the U.S. and most major international markets
outside of Japan, partially offset by growth in Japan. Zyprexa sales in Japan were approximately $585 million
in 2012, compared to approximately $540 million in 2011.
Sales of Humulin increased 1 percent in the U.S., driven by higher prices, largely offset by decreased
demand. U.S. sales of Humulin were negatively affected by the product's removal from a large formulary in
2012, as well as the continued decline in the market for human insulin and the termination of the Humulin
ReliOn agreement with Walmart. Sales outside the U.S. decreased 2 percent, driven by the unfavorable
impact of foreign exchange rates, partially offset by increased volume.
Sales of Forteo increased 8 percent in the U.S., driven by higher prices, partially offset by decreased volume.
Sales outside the U.S. increased 33 percent, primarily due to the increased demand in Japan.